Sangamo Therapeutics, Inc.

Less than two months after Pfizer opted to give up its rights to late-stage Sangamo Therapeutics-partnered hemophilia A gene therapy candidate giroctocogene fitelparvovec, the big pharma has decided t

BioMarin Pharmaceuticals foresees its achondroplasia drug Voxzogo (vosoritide) having a strong competitive position in the years to come given the drug’s established position and the “stickiness” of t

Sangamo Therapeutics ended 2024 with only enough cash to fund its operations into the first quarter of 2025, but CEO Sandy Macrae said he is confident an imminent deal for the company’s Fabry disease

In comparison to the broad S&P 500 index closing the year to 31 December 2024 up by over 24%, the fall by more than 3% in the NASDAQ Biotech Index (NBI) over the same period was a disaster. Specia